Compositions and Methods for Treating Collagen-Mediated Diseases

1 . A drug product comprising isolated and purified collagenase I and collagenase II having the sequence of Clostridium histolyticum collagenase I and collagenase II, respectively, wherein the collagenase I and collagenase II have a mass ratio of about 1 to 1 and the drug product is at least 95% by area pure as determined by reverse phase high performance liquid chromatography.

2 . The drug product of claim 1 , wherein the drug product contains less than about 2% by area aggregated protein as determined by reverse phase high performance liquid chromatography.

3 . The drug product of claim 1 , wherein the drug product contains less than about 1% by area of clostripain as determined by reverse phase high performance liquid chromatography.

4 . The drug product of claim 1 , wherein the drug product contains less than about 1% by area of gelatinase as determined by anion exchange chromatography.

5 . The drug product of claim 1 , wherein the drug product contains less than about 1 ug/mg (w/w) of leupeptin.

6 . The drug product of claim 1 , wherein the drug product has a bioburden less than 1 cfu/ml, and wherein the drug product is sterile.

7 . The drug product of claim 6 , wherein the drug product contains less than 10 EU/ml of endotoxin.

8 . The drug product of claim 6 , wherein the drug product contains less than 5 EU/mg of endotoxin.

9 . A drug product comprising isolated and purified collagenase I and collagenase II having the sequence of Clostridium histolyticum collagenase I and collagenase II, respectively, wherein the collagenase I and collagenase II have a mass ratio of about 1 to 1 and the drug product is at least 95% by area pure as determined by reverse phase high performance liquid chromatography, wherein the preparation of the drug product comprises the steps of:

a) fermenting Clostridium histolyticum;

b) harvesting a crude fermentation comprising collagenase I and collagenase II;

c) purifying collagenase I and collagenase II from the crude harvest via filtration and column chromatography comprising the steps of:

i) filtering the crude harvest through an anion exchange filter;

ii) adding ammonium sulphate;

iii) subjecting the harvest through a HIC column;

iv) adding leupeptin to the filtrate;

v) removing the ammonium sulfate;

vi) filtering the mixture of step (v); and

vii) separating collagenase I and collagenase II using ion-exchange;

d) combining the collagenase I and collagenase II purified from step (c) at a ratio of about 1 to 1.

10 . The drug product of claim 9 , wherein the drug product is at least 97% by area pure as determined by reverse phase high performance liquid chromatography.

11 . The drug product of claim 9 , wherein preparation of the drug product further comprises the step of conducting cell bank preparations in the presence of phytone peptone or vegetable peptone.

12 . The drug product of claim 9 , wherein the fermentation step comprises the steps of:

i. inoculating the medium in a first stage with Clostridium histolyticum and agitating the mixture;

ii. incubating the mixture from step (i) to obtain an aliquot;

iii. inoculating the medium in a second stage with aliquots resulting from step (ii) and agitating the mixture;

iv. incubating mixtures from step (iii) to obtain an aliquot;

v. inoculating the medium in a third stage with aliquots resulting from step (iv) and agitating;

vi. incubating mixtures from step (v) to obtain an aliquot;

vii. inoculating the medium in a fourth stage with an aliquot resulting from step (vi) and agitating; and

viii. incubating mixtures from step (vii).

13 . The drug product of claim 9 , wherein the drug product is stored at a temperature of about −70° C.

14 . A process for producing a drug product comprising isolated and purified collagenase I and collagenase II having the sequence of Clostridium histolyticum collagenase I and collagenase II, respectively, wherein the collagenase I and collagenase II have a mass ratio of about 1 to 1 and the drug product is at least 95% by area pure as determined by reverse phase high performance liquid chromatography, comprising the steps of:

a) fermenting Clostridium histolyticum;

b) harvesting a crude fermentation comprising collagenase I and collagenase II;

c) purifying collagenase I and collagenase II from the crude harvest via filtration and column chromatography comprising the steps of:

i) filtering the crude harvest through an anion exchange filter;

ii) adding ammonium sulphate;

iii) subjecting the harvest through a HIC column;

iv) adding leupeptin to the filtrate;

v) removing the ammonium sulfate;

vi) filtering the mixture of step (v); and

vii) separating collagenase I and collagenase II using ion-exchange;

d) combining the collagenase I and collagenase II purified from step (c) at a ratio of about 1 to 1.

15 . The process of claim 14 , wherein the drug product is at least 97% by area pure as determined by reverse phase high performance liquid chromatography.

16 . The process of claim 14 , further comprising the step of conducting cell bank preparations in the presence of phytone peptone or vegetable peptone.

17 . The process of claim 14 , wherein the fermentation step comprises the steps of:

i. inoculating the medium in a first stage with Clostridium histolyticum and agitating the mixture;

ii. incubating the mixture from step (i) to obtain an aliquot;

iii. inoculating the medium in a second stage with aliquots resulting from step (ii) and agitating the mixture;

iv. incubating mixtures from step (iii) to obtain an aliquot;

v. inoculating the medium in a third stage with aliquots resulting from step (iv) and agitating;

vi. incubating mixtures from step (v) to obtain an aliquot;

vii. inoculating the medium in a fourth stage with an aliquot resulting from step (vi) and agitating; and

viii. incubating mixtures from step (vii).

18 . The process of claim 14 , wherein the drug product is stored at a temperature of about −70° C.

19 . A pharmaceutical formulation comprising a pharmaceutically acceptable excipient and a drug product comprising isolated and purified collagenase I and collagenase II having the sequence of Clostridium histolyticum collagenase I and collagenase II, respectively, wherein the collagenase I and collagenase II have a mass ratio of about 1 to 1 and the drug product is at least 95% by area pure as determined by reverse phase high performance liquid chromatography.

20 . The pharmaceutical formulation of claim 19 , wherein the drug product is a sterile lyophilized powder and is stored at a temperature of about 5° C.

21 . The pharmaceutical formulation of claim 19 , wherein the formulation is a lyophilized injectable formulation formulated with Sucrose, Tris and with a pH level of about 8.0.

22 . The pharmaceutical formulation of claim 21 , wherein the formulation is a lyophilized injectable formulation comprising about 0.9 mg of the said drug product, about 18.5 mg of sucrose and about 1.1 mg of Tris, and wherein the targeting vial fill volume is about 0.9 mL.

23 . The pharmaceutical formulation of claim 21 , wherein the formulation is a lyophilized injectable formulation comprising about 0.58 mg of the said drug product, about 12.0 mg of sucrose and about 0.7 mg of Tris.

24 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a drug product comprising isolated and purified collagenase I and collagenase II having the sequence of Clostridium histolyticum collagenase I and collagenase II, respectively, wherein the collagenase I and collagenase II have a mass ratio of about 1 to 1 and the drug product is at least 95% by area pure as determined by reverse phase high performance liquid chromatography, wherein the preparation of the drug product comprises the steps of:

a) fermenting Clostridium histolyticum;

b) harvesting a crude fermentation comprising collagenase I and collagenase II;

c) purifying collagenase I and collagenase II from the crude harvest via filtration and column chromatography comprising the steps of:

i) filtering the crude harvest through an anion exchange filter;

ii) adding ammonium sulphate;

iii) subjecting the harvest through a HIC column;

iv) adding leupeptin to the filtrate;

v) removing the ammonium sulfate;

vi) filtering the mixture of step (v); and

vii) separating collagenase I and collagenase II using ion-exchange;

d) combining the collagenase I and collagenase II purified from step (c) at a ratio of about 1 to 1.

25 . The pharmaceutical composition of claim 24 , wherein the drug product is a sterile lyophilized powder.

26 . The pharmaceutical composition of claim 25 , wherein the composition is a lyophilized injectable composition formulated with sucrose, Tris and with a pH level of about 8.0.

27 . The pharmaceutical composition of claim 26 , wherein the formulation is a lyophilized injectable composition comprising about 0.9 mg of the said drug product, about 18.5 mg of sucrose and about 1.1 mg of Tris, and wherein the targeting vial fill volume is about 0.9 mL.

28 . The pharmaceutical composition of claim 26 , wherein the drug product is a lyophilized injectable composition comprising about 0.58 mg of the said drug product, about 12.0 mg of sucrose and about 0.7 mg of Tris.

29 . A drug product comprising collagenase I and collagenase II, wherein the collagenase I and collagenase II are isolated and purified from Clostridium histolyticum and wherein the collagenase I and collagenase II have a mass ratio of about 1 to 1 and the drug product is at least 97% by area pure as determined by reverse phase high performance liquid chromatography.

30 . The drug product of claim 29 , wherein the drug product contains less than about 2% by area aggregated protein as determined by reverse phase high performance liquid chromatography.

31 . The drug product of claim 29 , wherein the drug product contains less than about 1% by area of clostripain as determined by reverse phase high performance liquid chromatography.

32 . The drug product of claim 29 , wherein the drug product contains less than about 1% by area of gelatinase as determined by anion exchange chromatography.

33 . The drug product of claim 29 , wherein the drug product contains less than about 1 ug/mg (w/w) of leupeptin.

34 . The drug product of claim 29 , wherein the drug product has a bioburden less than 1 cfu/ml, and wherein the drug product is sterile.

35 . The drug product of claim 24 , wherein the drug product contains less than 10 EU/ml of endotoxin.

36 . The drug product of claim 6 , wherein the drug product contains less than 5 EU/mg of endotoxin.

37 . A drug product comprising isolated and purified collagenase I and collagenase II having the sequence of Clostridium histolyticum collagenase I and collagenase II, respectively, wherein the collagenase I and collagenase II have a mass ratio of about 1 to 1 and the drug product is at least 97% by area pure as determined by reverse phase high performance liquid chromatography, wherein the preparation of the drug product comprises the steps of:

a) fermenting Clostridium histolyticum;

b) harvesting a crude fermentation comprising collagenase I and collagenase II;

c) purifying collagenase I and collagenase II from the crude harvest via filtration and column chromatography comprising the steps of:

i) filtering the crude harvest through an anion exchange filter;

ii) adding ammonium sulphate;

iii) subjecting the harvest through a HIC column;

iv) adding leupeptin to the filtrate;

v) removing the ammonium sulfate;

vi) filtering the mixture of step (v); and

vii) separating collagenase I and collagenase II using ion-exchange;

d) combining the collagenase I and collagenase II purified from step (c) at a ratio of about 1 to 1.

38 . The drug product of claim 37 , wherein the drug product is at least 97% by area pure as determined by reverse phase high performance liquid chromatography.

39 . The drug product of claim 37 , wherein preparation of the drug product further comprises the step of conducting cell bank preparations in the presence of phytone peptone or vegetable peptone.

40 . The drug product of claim 37 , wherein the fermentation step comprises the steps of:

i. inoculating the medium in a first stage with Clostridium histolyticum and agitating the mixture;

ii. incubating the mixture from step (i) to obtain an aliquot;

iii. inoculating the medium in a second stage with aliquots resulting from step (ii) and agitating the mixture;

iv. incubating mixtures from step (iii) to obtain an aliquot;

v. inoculating the medium in a third stage with aliquots resulting from step (iv) and agitating;

vi. incubating mixtures from step (v) to obtain an aliquot;

vii. inoculating the medium in a fourth stage with an aliquot resulting from step (vi) and agitating; and

viii. incubating mixtures from step (vii).

41 . The drug product of claim 9 , wherein the drug product is stored at a temperature of about −70° C.

42 . A process for producing a drug product comprising isolated and purified collagenase I and collagenase II having the sequence of Clostridium histolyticum collagenase I and collagenase II, respectively, wherein the collagenase I and collagenase II have a mass ratio of about 1 to 1 and the drug product is at least 97% by area pure as determined by reverse phase high performance liquid chromatography, comprising the steps of:

a) fermenting Clostridium histolyticum;

b) harvesting a crude fermentation comprising collagenase I and collagenase II;

c) purifying collagenase I and collagenase II from the crude harvest via filtration and column chromatography comprising the steps of:

i) filtering the crude harvest through an anion exchange filter;

ii) adding ammonium sulphate;

iii) subjecting the harvest through a HIC column;

iv) adding leupeptin to the filtrate;

v) removing the ammonium sulfate;

vi) filtering the mixture of step (v); and

vii) separating collagenase I and collagenase II using ion-exchange;

d) combining the collagenase I and collagenase II purified from step (c) at a ratio of about 1 to 1.

43 . The process of claim 42 , wherein the drug product is at least 97% by area pure as determined by reverse phase high performance liquid chromatography.

44 . The process of claim 42 , further comprising the step of conducting cell bank preparations in the presence of phytone peptone or vegetable peptone.

45 . The process of claim 42 , wherein the fermentation step comprises the steps of:

i. inoculating the medium in a first stage with Clostridium histolyticum and agitating the mixture;

ii. incubating the mixture from step (i) to obtain an aliquot;

iii. inoculating the medium in a second stage with aliquots resulting from step (ii) and agitating the mixture;

iv. incubating mixtures from step (iii) to obtain an aliquot;

v. inoculating the medium in a third stage with aliquots resulting from step (iv) and agitating;

vi. incubating mixtures from step (v) to obtain an aliquot;

vii. inoculating the medium in a fourth stage with an aliquot resulting from step (vi) and agitating; and

viii. incubating mixtures from step (vii).

46 . The process of claim 42 , wherein the drug product is stored at a temperature of about −70° C.

47 . A pharmaceutical formulation comprising a pharmaceutically acceptable excipient and a drug product comprising isolated and purified collagenase I and collagenase II having the sequence of Clostridium histolyticum collagenase I and collagenase II, respectively, wherein the collagenase I and collagenase II have a mass ratio of about 1 to 1 and the drug product is at least 97% by area pure as determined by reverse phase high performance liquid chromatography.

48 . The pharmaceutical formulation of claim 47 , wherein the drug product is a sterile lyophilized powder and is stored at a temperature of about 5° C.

49 . The pharmaceutical formulation of claim 47 , wherein the formulation is a lyophilized injectable formulation formulated with Sucrose, Tris and with a pH level of about 8.0.

50 . The pharmaceutical formulation of claim 49 , wherein the formulation is a lyophilized injectable formulation comprising about 0.9 mg of the said drug product, about 18.5 mg of sucrose and about 1.1 mg of Tris, and wherein the targeting vial fill volume is about 0.9 mL.

51 . The pharmaceutical formulation of claim 49 , wherein the formulation is a lyophilized injectable formulation comprising about 0.58 mg of the said drug product, about 12.0 mg of sucrose and about 0.7 mg of Tris.

52 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a drug product comprising isolated and purified collagenase I and collagenase II having the sequence of Clostridium histolyticum collagenase I and collagenase II, respectively, wherein the collagenase I and collagenase II have a mass ratio of about 1 to 1 and the drug product is at least 97% by area pure as determined by reverse phase high performance liquid chromatography, wherein the preparation of the drug product comprises the steps of:

a) fermenting Clostridium histolyticum;

b) harvesting a crude fermentation comprising collagenase I and collagenase II;

c) purifying collagenase I and collagenase II from the crude harvest via filtration and column chromatography comprising the steps of:

i) filtering the crude harvest through an anion exchange filter;

ii) adding ammonium sulphate;

iii) subjecting the harvest through a HIC column;

iv) adding leupeptin to the filtrate;

v) removing the ammonium sulfate;

vi) filtering the mixture of step (v); and

vii) separating collagenase I and collagenase II using ion-exchange;

d) combining the collagenase I and collagenase II purified from step (c) at a ratio of about 1 to 1.

53 . The pharmaceutical composition of claim 52 , wherein the drug product is a sterile lyophilized powder.

54 . The pharmaceutical composition of claim 52 , wherein the composition is a lyophilized injectable composition formulated with sucrose, Tris and with a pH level of about 8.0.

55 . The pharmaceutical composition of claim 54 , wherein the formulation is a lyophilized injectable composition comprising about 0.9 mg of the said drug product, about 18.5 mg of sucrose and about 1.1 mg of Tris, and wherein the targeting vial fill volume is about 0.9 mL.

56 . The pharmaceutical composition of claim 54 , wherein the drug product is a lyophilized injectable composition comprising about 0.58 mg of the said drug product, about 12.0 mg of sucrose and about 0.7 mg of Tris.